• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,094
79
60
57
47

COUNTRY

55
17
8
6
5

CATEGORIES

  • 82
  • 121
  • 66
  • 66
  • 36
  • 37
  • 12
  • 11
  • 12
  • 18

PRICE

544
811
1,671
2,601

PUBLISHED

213
293
747
2,601

PRODUCT TYPE

2,454
72
62
12
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
TSLP Signaling Pathway in Oncology Drug Pipeline Update 2015 TSLP Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

TSLP Signaling Pathway in Oncology Drug Pipeline Update 2015

Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine that play various roles in a broad spectrum of biological procedures. TSLP can be secreted by epithelial cells upon pathogen stimulation....

January 2015
FROM
Breast Cancer Drug Pipeline Update 2015 Breast Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Breast Cancer Drug Pipeline Update 2015

Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic...

January 2015
FROM
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2015 IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2015

The IL-3 signaling pathway activates the JAK/STAT, MAPK and PI 3-kinase signaling modules. There are today 192 companies plus partners developing 243 IL-3 pathway targeting drugs in 1001 developmental...

January 2015
FROM
Lymphoma Drug Pipeline Update 2015 Lymphoma Drug Pipeline Update 2015 - Product Thumbnail Image

Lymphoma Drug Pipeline Update 2015

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today 263 companies plus partners developing 378 lymphoma drugs in 694 developmental projects in cancer....

January 2015
FROM
Gene Therapy in Oncology Drug Pipeline Update 2015 Gene Therapy in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Gene Therapy in Oncology Drug Pipeline Update 2015

There are today 122 companies plus partners developing 100 gene therapy drugs in 280 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs...

January 2015
FROM
Hematological Cancers Drug Pipeline Update 2015 Hematological Cancers Drug Pipeline Update 2015 - Product Thumbnail Image

Hematological Cancers Drug Pipeline Update 2015

Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. There are today 485 companies plus partners developing...

January 2015
FROM
Bladder Cancer Drug Pipeline Update 2015 Bladder Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Bladder Cancer Drug Pipeline Update 2015

According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 year survival rate...

January 2015
FROM
Leukemia Drug Pipeline Update 2015 Leukemia Drug Pipeline Update 2015 - Product Thumbnail Image

Leukemia Drug Pipeline Update 2015

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today 318 companies plus partners developing 416 leukemia drugs in 668 developmental...

January 2015
FROM
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2015 IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2015

The IL-5 singaling pathway activates the JAK/STAT and Raf/MAPK signaling modules. There are today 128 companies plus partners developing 156 IL-5 pathway targeting drugs in 710 developmental projects...

January 2015
FROM
Proteins in Oncology Drug Pipeline Update 2015 Proteins in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Proteins in Oncology Drug Pipeline Update 2015

This drug pipeline update covers proteins, excluding antibodies, as drugs for the treatment of cancer. There are today 332 companies plus partners developing 331 protein drugs in 687 developmental...

January 2015
FROM
Angiogenesis in Oncology Drug Pipeline Update 2015 Angiogenesis in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Angiogenesis in Oncology Drug Pipeline Update 2015

There are today 317 companies plus partners developing 350 angiogenesis drugs in 1693 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased...

January 2015
FROM
Biologicals in Oncology Drug Pipeline Update 2015 Biologicals in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Biologicals in Oncology Drug Pipeline Update 2015

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 980 companies plus partners developing 1676...

January 2015
FROM
Antibodies in Oncology Drug Pipeline Update 2015 Antibodies in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Antibodies in Oncology Drug Pipeline Update 2015

The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the...

January 2015
FROM
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2015 Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2015

Aberrant activation of the Hedgehog pathway has been associated with a number of human malignancies including carcinoma of lung, esophagus, pancreas and prostate. There are today 123 companies plus...

January 2015
FROM
Brain Cancer Drug Pipeline Update 2015 Brain Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Brain Cancer Drug Pipeline Update 2015

Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases...

January 2015
FROM
Apoptosis in Oncology Drug Pipeline Update 2015 Apoptosis in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Apoptosis in Oncology Drug Pipeline Update 2015

Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis...

January 2015
FROM
IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2015 IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2015

The IL-4 signaling pathway stimulates the JAK/STAT and MAPK signaling modules. There are today 155 companies plus partners developing 191 IL-4 pathway targeting drugs in 739 developmental projects...

January 2015
FROM
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2015 Nucleic Acid Therapies in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Nucleic Acid Therapies in Oncology Drug Pipeline Update 2015

Nucleic acid therapies in oncology includes: Gene Therapy, DNA vaccine, Other DNA technologies, RNA Interference (RNAi), Small interfering RNA (siRNA), Antisense RNA and Ribozymes. There are today...

January 2015
FROM
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2015 IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2015

The IL-1 signaling pathway activates the MAPK/JNK signaling modules. The MAPK pathway leads to activation of NFkB complex. As both IL-1 and TNF alpha stimulate the MAPK signaling module and activate...

January 2015
FROM
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2015 Wnt Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Wnt Signaling Pathway in Oncology Drug Pipeline Update 2015

Abnormalities in the Wnt signaling pathway are associated with a large variety of human malignancies including tumors of breast, colon, pancreas, liver and bone. There are today 186 companies plus...

January 2015
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)